Pombiliti Opfolda Cipaglucosidase Miglustat Pompe Disease 2026
Author: Critical Kare PharmaNeuromuscular & Rare Disease Desk
On November 19, 2026, neuromuscular and rare metabolic disorder congresses reviewed multi-year clinical registries for Pombiliti® (Cipaglucosidase alfa-atga 105 mg vial) co-administered with Opfolda® (Miglustat 65 mg capsules) by Amicus Therapeutics in late-onset Pompe disease (LOPD).
As the first two-component enzyme replacement therapy (ERT) engineered with a chemical chaperone, the regimen addresses the key historical limitation of classic alglucosidase alfa: inadequate cellular enzyme uptake and lysosomal mistargeting in skeletal muscle.
Through Critical Kare Pharma, genuine certified supplies of Pombiliti and Opfolda packages are distributed to neuromuscular referral hospitals, named patients, and metabolic genetics clinics globally.
The Two-Component Scientific Breakthrough
- High Bis-M6P Glyco-engineering: Cipaglucosidase alfa is expressed with high levels of bis-phosphorylated mannose-6-phosphate (bis-M6P) N-glycans, providing up to 15-fold greater binding affinity to cation-independent M6P receptors (CI-MPR) on muscle cell membranes.
- Opfolda Oral Enzyme Chaperone: Miglustat is taken orally 1 hour before infusion. It binds selectively to cipaglucosidase alfa in the bloodstream, stabilizing its active conformation at neutral pH and preventing premature denaturation before it reaches target lysosomes.
- Lysosomal Clearance: Upon acidification inside muscle lysosomes, miglustat dissociates, leaving fully active acid alpha-glucosidase (GAA) to clear accumulated glycogen.
PROPEl Phase 3 Registry Evidence
In patients switched from standard alglucosidase alfa, the cipaglucosidase alfa + miglustat combination demonstrated superior stabilization of forced vital capacity (FVC% predicted) and statistically significant improvements in the 6-Minute Walk Test (6MWT) distance over 52 and 104 weeks.
Administration & Named-Patient Logistics
Infusions are given every two weeks under strict weight-based protocols. Critical Kare Pharma ensures temperature-validated cold-chain delivery (2°C–8°C for Pombiliti) alongside room-temperature Opfolda dispatch under comprehensive certificate of analysis (COA) compliance.



